PROMETAX is a brand name for Rivastigmine, a medication primarily used in the management and treatment of mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. Rivastigmine belongs to a class of drugs known as cholinesterase inhibitors, which work by increasing the levels of acetylcholine, a chemical messenger involved in memory and learning, in the brain. By doing so, PROMETAX aims to slow down the progression of symptoms related to cognitive decline, such as memory loss, confusion, and difficulties with thinking and reasoning. It is available in various forms, including capsules, oral solution, and transdermal patches, offering flexibility in administration based on patient needs and preferences. Like all medications, PROMETAX can have side effects, and its use should be closely monitored by healthcare professionals to ensure its efficacy and safety for individual patients.